Pfizer Inc Stock Net Income
| PFE Stock | USD 26.32 0.06 0.23% |
Pfizer Inc fundamentals help investors to digest information that contributes to Pfizer's financial success or failures. It also enables traders to predict the movement of Pfizer Stock. The fundamental analysis module provides a way to measure Pfizer's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pfizer stock.
| Last Reported | Projected for Next Year | ||
| Net Income | 2.1 B | 2 B | |
| Net Income Applicable To Common Shares | 36.1 B | 37.9 B | |
| Net Income From Continuing Ops | 2.2 B | 2.1 B | |
| Net Income Per Share | 0.38 | 0.36 | |
| Net Income Per E B T | 2.00 | 2.10 |
Pfizer | Net Income |
Pfizer Inc Company Net Income Analysis
Pfizer's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Pfizer Net Income | 2.13 B |
Most of Pfizer's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pfizer Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Pfizer Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Pfizer is extremely important. It helps to project a fair market value of Pfizer Stock properly, considering its historical fundamentals such as Net Income. Since Pfizer's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pfizer's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pfizer's interrelated accounts and indicators.
Pfizer Net Income Historical Pattern
Today, most investors in Pfizer Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Pfizer's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's net income growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Pfizer net income as a starting point in their analysis.
Pfizer Net Income |
| Timeline |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Pfizer Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Pfizer Inc reported net income of 2.13 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is significantly lower than that of the firm.
Pfizer Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pfizer's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pfizer could also be used in its relative valuation, which is a method of valuing Pfizer by comparing valuation metrics of similar companies.Pfizer is currently under evaluation in net income category among related companies.
Pfizer ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pfizer's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pfizer's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Pfizer Institutional Holders
Institutional Holdings refers to the ownership stake in Pfizer that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Pfizer's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Pfizer's value.| Shares | State Farm Mutual Automobile Ins Co | 2023-12-31 | 54.5 M | Legal & General Group Plc | 2023-12-31 | 49.6 M | Goldman Sachs Group Inc | 2023-12-31 | 48.1 M | Bank Of America Corp | 2023-12-31 | 47.9 M | Bank Of New York Mellon Corp | 2023-12-31 | 44.1 M | Amundi | 2023-12-31 | 42.6 M | Jpmorgan Chase & Co | 2023-12-31 | 42.4 M | Dimensional Fund Advisors, Inc. | 2023-12-31 | 42 M | Deutsche Bank Ag | 2023-12-31 | 40.2 M | Vanguard Group Inc | 2023-12-31 | 506.5 M | Blackrock Inc | 2023-12-31 | 432.5 M |
Pfizer Fundamentals
| Return On Equity | 0.0235 | ||||
| Return On Asset | 0.0155 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | (0.50) % | ||||
| Current Valuation | 211.2 B | ||||
| Shares Outstanding | 5.66 B | ||||
| Shares Owned By Insiders | 0.04 % | ||||
| Shares Owned By Institutions | 69.95 % | ||||
| Number Of Shares Shorted | 65 M | ||||
| Price To Earning | 9.48 X | ||||
| Price To Book | 1.65 X | ||||
| Price To Sales | 2.50 X | ||||
| Revenue | 58.5 B | ||||
| Gross Profit | 66.23 B | ||||
| EBITDA | 10.53 B | ||||
| Net Income | 2.13 B | ||||
| Cash And Equivalents | 2.85 B | ||||
| Cash Per Share | 6.44 X | ||||
| Total Debt | 75.04 B | ||||
| Debt To Equity | 0.40 % | ||||
| Current Ratio | 1.59 X | ||||
| Book Value Per Share | 15.77 X | ||||
| Cash Flow From Operations | 8.7 B | ||||
| Short Ratio | 1.40 X | ||||
| Earnings Per Share | 0.37 X | ||||
| Price To Earnings To Growth | 0.26 X | ||||
| Target Price | 31.1 | ||||
| Number Of Employees | 88 K | ||||
| Beta | 0.57 | ||||
| Market Capitalization | 148.7 B | ||||
| Total Asset | 226.5 B | ||||
| Retained Earnings | 118.35 B | ||||
| Working Capital | (4.46 B) | ||||
| Current Asset | 43.8 B | ||||
| Current Liabilities | 29.4 B | ||||
| Annual Yield | 0.06 % | ||||
| Five Year Return | 3.60 % | ||||
| Net Asset | 226.5 B | ||||
| Last Dividend Paid | 1.64 |
About Pfizer Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pfizer Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pfizer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pfizer Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Pfizer Piotroski F Score and Pfizer Altman Z Score analysis. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Dividend Share 1.64 | Earnings Share 0.37 | Revenue Per Share 10.366 | Quarterly Revenue Growth (0.41) |
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.